Josephine Deguzman, MD
Psychiatry · Oklahoma City, OKNPI 1043391675
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,160 of the $37,582 with a category attached, or 72.3%. Teva Pharmaceuticals USA, Inc. accounts for 84.1% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $32,308, more than ten times the $327 reported in 2019. Among psychiatry clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 472 payments — averaging $79.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$32K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$839
- Johnson & Johnson$836
- Vanda Pharmaceuticals Inc.$580
- AbbVie$522
- plus $2K from 10 others
What the payments were for
- Consulting fees$6352%
- Speaking & faculty fees$27,16072%
- Travel & lodging$2,5297%
- Food & beverage$7,14719%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 80 | $31,601 |
| Alkermes, Inc. | 68 | $1,160 |
| Neurocrine Biosciences, Inc. | 60 | $839 |
| Johnson & Johnson | 68 | $836 |
| Vanda Pharmaceuticals Inc. | 31 | $580 |
| AbbVie(2 entities) | 56 | $522 |
| Otsuka America Pharmaceutical, Inc. | 21 | $382 |
| Lundbeck LLC | 19 | $368 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $350 |
| Indivior Inc. | 25 | $343 |
| E.r. Squibb & Sons, L.L.C. | 8 | $238 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $175 |
| Alk-abello, Inc | 1 | $68 |
| Sunovion Pharmaceuticals Inc. | 8 | $62 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Braeburn Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$16,696
- Austedo XR$13,914
- ABILIFY MYCITE$175
- COBENFY$122
How this compares
$37,582 in reported general payments places this provider in the 95th percentile of 328 psychiatry providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 52 | $367,842 |
| Invega SustennaPaliperidone Palmitate | 109 | $342,996 |
| Invega TrinzaPaliperidone Palmitate | 17 | $162,358 |
| AristadaAripiprazole Lauroxil | 43 | $129,817 |
| Abilify MaintenaAripiprazole | 16 | $45,837 |
| Risperdal ConstaRisperidone Microspheres | 26 | $43,926 |
| PerserisRisperidone | 14 | $40,035 |
| Clozapine OdtClozapine | 37 | $7,229 |
| Paliperidone ErPaliperidone | 34 | $3,819 |
| Fluphenazine Hcl | 34 | $3,324 |
| Haloperidol Decanoate | 53 | $2,735 |
| Clozapine | 28 | $2,107 |
| Benztropine Mesylate | 175 | $1,816 |
| Fluvoxamine Maleate | 24 | $1,358 |
| Olanzapine OdtOlanzapine | 16 | $1,351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $836 | $549,280152 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $31,601 | $367,84252 claims |
| Alkermes, Inc.Aristada | $1,160 | $129,81743 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $382 | $45,83716 claims |
| Indivior Inc.Perseris | $343 | $40,03514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 328 psychiatry providers in Oklahoma.
Other psychiatry in Oklahoma City
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Haisam Al KhouriOklahoma City$10K
- Patrick HornOklahoma City$8K
- Shreekuma VinekarOklahoma City$7K
- Relindis TitaOklahoma City$6K
- Janita ArdisOklahoma City$6K
- Fiona LiOklahoma City$5K
- Ahsan KhanOklahoma City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.